{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-195895","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.697177+00:00","generated_at":"2026-05-31T11:46:10.987575+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atea reports Q2 net loss $40.5M; Phase 2 HCV data show 97% SVR12; Phase 3 COVID-19 trial due 2H24","bullets":["Net loss of $40.5M for Q2 2024 (diluted EPS -$0.48) vs $28.2M loss in Q2 2023; cash balance $502.2M.","R&D expenses rose to $34.7M (+$12.6M YoY) driven by Phase 2/3 trial costs.","Full enrollment in global Phase 2 HCV study (bemnifosbuvir + ruzasvir); SVR12 results expected 4Q 2024.","Lead-in cohort (n=60) at EASL achieved 97% SVR12 with 8-week treatment; no drug-related serious AEs.","Phase 3 SUNRISE-3 (bemnifosbuvir for COVID-19) topline data anticipated in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-195895","json":"https://secwatch.observer/filing/0001193125-24-195895.json","markdown":"https://secwatch.observer/filing/0001193125-24-195895.md","text":"https://secwatch.observer/filing/0001193125-24-195895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524195895/0001193125-24-195895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524195895/d880974d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:46:10.987575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}